(secondQuint)Trial of Montelukast in Eosinophilic Esophagitis.

 We will randomize in a double blind manner 60 consecutive consenting patients being evaluated at the three Mayo Clinic Medical Centers with EE to montelukast 20mg daily or placebo daily for six months? time.

 Patients will be in remission after treatment with topical fluticasone therapy before enrollment.

 Patients will fill out a validated dysphagia and side effect questionnaire before, during, and at the end of therapy.

.

 Trial of Montelukast in Eosinophilic Esophagitis@highlight

Evaluate clinical effectiveness of oral montelukast compared to placebo on prevention of dysphagia and food impaction in patients with EE.

 Also evaluate tolerance and safety of oral montelukast in treatment of EE.

